Cutaneous squamous cell carcinoma
- Humans1
Effects
1CDKN1A
downin humans1−44%
1 study
CDKN1A
downin humans1−44%
Cutaneous squamous cell carcinoma decreases CDKN1A in humans (43.9%).
“In invasive cSCC, p21CIP1 fell to 43.9% and tumor suppressor p53 immunoreactivity often declined, whereas cyclin-dependent kinase inhibitor p16 (p16INK4a) commonly accumulated without arrest”
Reviewin invasive cutaneous squamous cell carcinomaskin
International journal of molecular sciences4 Feb 2026
Trial sponsors
Company1 trialPhase 149 people
3 trialsPhase 4117 people
The Netherlands Cancer Institute
2 trialsPhase 291 people
Washington University School of Medicine
1 trialPhase 222 people
1 trialPhase 214 people
1 trialPhase 1/248 people
University of Southern California
1 trialPhase 114 people
1 trialEarly phase 120 people
Latest
3 in 12 monthsbioRxiv
Non-invasive forecasting of skin cancer evolution through longitudinal hair sampling
Preprint: experiments in animalsSkin
Research Square
Menopausal Hormone Replacement Therapy and Association with Actinic Keratoses and Skin Cancer: A Retrospective Cohort Study
Preprint: cohort study in peopleSkin cancer
International Journal of Molecular Sciences
Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review
Systematic review of observational studiesBiomarkers